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Abstract The aim of this study was to investigate human
invasive isolates of enterococci, obtained through prospec-
tive surveillance in Poland. The consecutive enterococcal
isolates were collected in 30 hospitals between May 2010
and June 2011, and studied by species identification, anti-
microbial susceptibility testing and, for Enterococcus
faecium by detection of markers specific for the hospital
meroclone, multilocus VNTR analysis (MLVA) and
multilocus sequence typing (MLST). Additionally, the ge-
nomic difference regions (GDRs) characteristic for lineage
78 were searched by PCR. Among 259 isolates, a nearly
equal number of Enterococcus faecalis (n= 140; 54.1 %)
and E. faecium (n= 112; 43.2 %) was found. The observed
14-day mortality rate of infected patients reached 18.1 %.
All isolates were susceptible to linezolid and daptomycin.
High-level aminoglycoside resistance occurred in over
50 % of isolates. Vancomycin resistance mediated by
vanA or vanB was detected in 7.1 % of E. faecium;
71.4 % of isolates were multidrug resistant. E. faecium
isolates ubiquitously carried molecular markers of
hospital-associated meroclone (IS16, espEfm, intA of
ICEEfm1) and multilocus sequence typing showed the
domination of representatives of lineages 78 and 17/18
(52.7 % and 46.4 %, respectively). Isolates of lineage 78
were significantly enriched in all the GDRs studied. The
recent spread of E. faecium from this lineage contributed to
the observed increase of E. faecium in enterococcal inva-
sive infections in hospitals in Poland.
Introduction
Bacteria belonging to the genus Enterococcus are a part of
the normal, harmless faecal flora of humans and animals.
However, they may also act as opportunistic pathogens,
and today are recognized as important causative agents of
both invasive and non-invasive nosocomial infections, af-
fecting immunocompromised, severely ill patients [1].
According to the European Centre for Disease Prevention
and Control (ECDC) enterococci are presently third, after
Escherichia coli and Staphylococcus aureus, most fre-
quently isolated bacteria from the healthcare-associated in-
fections (HAIs) in Europe [2]. Currently observed acquisi-
tion of resistance to antimicrobials used in the therapy of
enterococcal infections is a cause of growing concern [3].
Enterococcus faecalis and Enterococcus faecium represent
two species of the biggest clinical importance, while infec-
tions caused by other enterococci are rare [4]. Multilocus
sequence typing (MLST) and other typing methods
showed the presence of distinct clones associated with hos-
pital infections/outbreaks, named high-risk enterococcal
clonal complexes (HiRECCs), within populations of both
E. faecalis and E. faecium [5, 6]. Genomes of isolates be-
longing to HiRECCs are enriched in mobile genetic ele-
ments (MGEs), often associated with genes encoding po-
tential virulence factors and resistance determinants [3, 7].
For E. faecalis, two HIRECCs, CC6 (also known as CC2)
and CC87, preferentially group hospital clinical isolates
[8]. Hospital subpopulation of E. faecium, initially
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described as CC17, was subsequently divided into three
lineages, 17, 18, and 78, named after the major sequence
type (ST) in each group [9, 10]. Analysis of the MLST data
using so-called Bayesian analysis of population structure
(BAPS) delimited two groups in the hospital meroclone, 2–
1, and 3–3, corresponding to lineages 78 and 17/18 respec-
tively [10]. Acquisition of ampicillin and ciprofloxacin re-
sistance, and the presence of the transferable pathogenicity
island (ICEEfm1), harbouring the espEfm gene, are consid-
ered important adaptive features of hospital meroclone of
E. faecium [11]. Genomic analyses indicated the presence
of seven additional regions in the genome of ST203 strain
from lineage 78 in comparison to lineage 17/18 [12].
The epidemiology of invasive enterococcal infections in
Polish hospitals is monitored by a systematic passive surveil-
lance performed by the National Reference Centre for
Susceptibility Testing, located at the National Medicines
Institute in Warsaw. However, considering the importance of
enterococcal infections, we decided to undertake a study
based on enhanced surveillance in selected hospitals during
a pre-defined period of time. Objectives of this study were to
collect enterococcal isolates from normally sterile body sites
together with the relevant clinical data, and to evaluate species
distribution and antibiotic susceptibility of these isolates.
Additionally, we aimed at more profound phenotypic and mo-
lecular characterization of E. faecium isolates, as the clinical
importance of this enterococcal species is recently increasing
in several countries [13], to search for a possible reason of this
phenomenon.
Materials and methods
Bacterial isolates and phenotypic testing Consecutive inva-
sive isolates of Enterococcus spp. (a single strain per patient
from normally sterile body fluids, such as blood, pleural fluid,
cerebrospinal fluid, and peritoneal fluid) were collected in 30
collaborating hospitals, located in 26 cities in all regions of
Poland, between May 2010 and June 2011. All patient data
were collected anonymously in the questionnaire formulated
for the purpose of the study. A nosocomial infection was de-
fined as infection which was caused by a strain isolated after
48 hours from admission to the hospital or earlier when patient
was transferred from another hospital. Enterococcal isolates
were re-identified in the central laboratory by conventional
methods, and using the mass spectrometer MALDI Biotyper
(Brücker, Bremen, Germany) and Vitek MS (bioMérieux,
Marcy l’Etoile, France) for selected isolates. For
Enterococcus hirae, Enterococcus durans, and Enterococcus
avium identification was conducted additionally with VITEK
2 Compact (bioMérieux). Antimicrobial susceptibility testing
for ampicillin, penicillin, imipenem, vancomycin, teicoplanin,
gentamicin, streptomycin, linezolid, tigecycline, tetracycline,
chloramphenicol, rifampin, ciprofloxacin, quinupristin–
dalfopristin and trimethoprim–sulfamethoxazole was per-
formed using the broth microdilution method according to
the Clinical and Laboratory Standard Institute guidelines
(CLSI), and for daptomycin the Etest method (bioMérieux).
The reference strain E. faecalis ATCC 29212 was used for
quality control. Obtained results were interpreted using avail-
able 2015 breakpoints of The European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (http://
www.eucast .org/ ) and the CLSI breakpoints for
antimicrobials for which the EUCAST breakpoints were not
available. Isolates were considered multidrug-resistant
(MDR) when they showed resistance to three or more classes
of antimicrobials tested [14]. Biofilm formation was evaluated
by the quantitative adherence assay in Trypticase Soy Broth
with 0.25 % glucose [15], and isolates were classified as bio-
film non-producers, weak and strong producers, based on the
results of staining with crystal violet [16].
DNA isolation, gene detection, molecular typing and data
analysis Total DNA was isolated using the Genomic DNA
Prep Plus kit according to the manufacturer’s instructions
(A&A Biotechnology, Gdynia, Poland). Detection of espEfm
and IS16 in E. faecium was performed by PCR as previously
described [17, 18]. The intAICEEfm1 gene, encoding the
integrase of ICEEfm1 was detected by PCR with primers de-
signed in this study: intA_up2 (5′-AATTGATTCGA
TAGTTTAGGTA-3') and intA_dn2 (5′-AATCACTTGCT
TACTCTTCAT -3′). E. faecium isolates positive for IS16,
espEfm and intA from our laboratory collection [19] served as
positive controls. Vancomycin nonsusceptibility determinants
vanA, vanB, and vanC were detected as previously described
[20, 21], with E. faecium BM4147, E. faecalis V583, and
Enterococcus gallinarum BM4147 used as respective positive
controls. E. faecium isolates were analysed by multiple-locus
variable-number tandem repeat (VNTR) analysis (MLVA) ac-
cording to Top et al. [22] and MLST [5], using the MLST
database (http://pubmlst.org/efaecium/) to determine allele
numbers and STs (21st April 2015, date accessed). New
alleles and allelic profiles were submitted to the above
database. MLST data were analyzed with the comparative
eBURST analysis against the whole E. faecium database
(http://eburst.mlst.net/; 21st April 2015, date accessed).
Genomic difference regions (named herein GDRs),
differentiating lineages 78 and 17/18 [12], were detected by
PCR using primers specific for genes located in these GDRs,
based on available genomic sequences (GenBank Accession
number NC_021994; Table 1). Differences in distributions
were assessed using the chi-squared test with p value≤0.05
considered significant. Antibiotic susceptibility data analysis
with the 95 % confidence intervals for the calculation of re-
sistance ratio was done using the WHONET (http://www.
whonet.org).
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Results
Enterococcal species Altogether, 259 invasive enterococcal
isolates were obtained during the collection period. For 247
(95.4 %) of them, the identification by MALDI Biotyper was
consistent with the results obtained with conventional
methods and Vitek 2 Compact. For the remaining 12 isolates,
additional identification with Vitek MS was used, and its re-
sults were in the agreement with the results from MALDI
Biotyper in three cases (one isolate of E. faecalis, E. faecium
and E. durans each), while in nine cases identification with the
Vitek MS confirmed the results of conventional methods (for
three E. faecalis, five E. faecium and one E. casseliflavus).
Thus, collected isolates comprised 140 strains of E. faecalis
(54.1 %), 112 of E. faecium (43.2 %) and seven isolates
(2.7 %) of other Enterococcus spp.: three E. gallinarum, two
E. durans, and single representatives of E. avium and
E. casseliflavus.
Hospitals involved in the study and patients’ data Isolates
were obtained from 30 collaborating hospitals (8.6 isolates per
hospital). Hospitals involved in the study included secondary
and tertiary hospitals, mainly of regional coverage (17 provin-
cial hospitals), but also district hospitals (n=5), specialist
(n=4) and university (n=4) hospitals. The numbers of iso-
lates collected from each type of ward are presented in
Table 2. For five strains, wards of hospitalization were not
given. A significant proportion of enterococcal invasive infec-
tions were nosocomial infections, i.e., 65.7 % and 78.6 % of E.
faecalis and E. faecium infections respectively. One hundred
and forty-five patients (56.0 %) with enterococcal invasive in-
fections were males and 109 (42.1 %) were females; the gender
of five patients (1.9 %) was not reported. The age of patients’
ranged from a newborn to 89 years, and the vast majority of
isolates (196, i.e., 75.6 %) was obtained from patients aged
above 50 years (Fig. 1). The most frequently reported types of
infection were bloodstream infections (Table 2), including
bacteraemia, septicaemia, and endocarditis (82.9 % of infec-
tions caused by E. faecalis and 75.0 % infections caused by
E. faecium) followed by abdominal infections (mainly perito-
nitis), meningitis, and chest and pelvic infections (mainly ab-
scess). Most of the bacteraemia/septicaemia cases had a known
focus (E. faecalis 59.3 %, E. faecium 53.6 %). The ratio of
bloodstream infections to abdominal infections for
E. faecaliswas 6.4:1 and for E. faecium 3.8:1, and the observed
differences in the ratio of bloodstream infections was statisti-
cally significant (p=0.011).
The data concerning risk factors were available for 165
(63.7 %) of patients, and indicated special importance of pre-
vious hospitalization during the previous 6 months (n=124;
75.2 % cases), surgery (n= 42; 25.4 %) and an ICU stay
(n=35; 21.2 %). Only one patient was reported as a nursing
home resident. The reported co-morbidities were: malignancy
(n=21; 13.9 %), chronic renal disease (n=7; 4.6 %), diabetes
(n=4; 2.6 %), and injury (n=5; 3.3 %). The outcome of treat-
ment of patients with enterococcal infections was reported for
243 cases (93.8 %). Due to the persistence of infection,
2 weeks after strain isolation more than half of the patients
(53.7 %) were still receiving antimicrobial treatment, while
only 23.2% of patients were successfully cured. The observed
overall 14-day mortality rate reached 18.1 % (44 patients;
Table 2). Fatal cases were reported in patients aged above
25 years, and mortality showed an increase with age
(Fig. 1). The highest mortality ratio was reported for menin-
gitis (one of three) and septicaemia (30.2 %, 16 of 53). A
higher mortality in E. faecium infections (23 cases, 21.5 %)
than these caused by E. faecalis (20 cases, 15.4 %) was ob-
served, however, without statistical significance (p=0.22). A
single case of fatal septicaemia in an oncology patient infected
with E. gallinarum was reported (Table 2). In two cases,
VREm infections proved fatal (28.6 % mortality, i.e., two
out of seven cases with the reported outcome), while for
vancomycin-susceptible strains this value was 21.0 % (21 of
100 with the reported outcome).
Table 1 Primers targeting the genomic difference regions
Primer Sequence 5′- > 3′ Gene in AUS0085 (ST203) Gene product PCR product size
Efm_R1_up AATCGATGACGTGGAAGAAGG Ef_aus00245 cadmium_translocating P-type ATPase 411 bp
Efm_R1_dn GACTAAAGCGCCAGGACAAC
Efm_R2_up ATGTTGCCCAAAAGACGAACC Ef_aus 01495 riboflavin biosynthesis protein RibD 153 bp
Efm_R2_dn GGAACGGCTAAAACAAGAAGC




Efm_R5_up CGTGCGTTCCTTTTTCTACC Ef_aus 02504 bacteriocin-like protein EntT 368 bp
Efm_R5_dn GGTTTAGATAGCCCACCAAG




Efm_R7_up TCAGCAAATGATGGCGATACG Ef_aus 02778 glycosyl hydrolase family 38 protein 374 bp
Efm_R7_dn ACCAATTCGGAGGAATGACATC
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Antimicrobial susceptibility of isolates and biofilm pro-
duction by E. faecium All isolates were susceptible to
linezolid and daptomycin (Table 3), and all E. faecalis
isolates were also susceptible to ampicillin, vancomycin
and teicoplanin. Over 50 % of isolates of both species
showed high-level resistance to aminoglycosides. Among
E. faecium isolates, very high ratios of resistance to am-
picillin, ciprofloxacin, and rifampin were observed, and
vancomycin resistance was detected in eight isolates
(VREfm); five of them showed VanA phenotype and the
presence of vanA. The three remaining VREfm carried the
vanB gene. Altogether, 71.4 % of isolates were classified
as multidrug resistant (MDR) [14]. This phenotype was
specific for nearly all isolates of E. faecium (109 isolates,
97.3 %) and 73 isolates (52.1 %) of E. faecalis. Only four
among 112 isolates of E. faecium (3.6 %) were identified
as biofilm producers, including three strong producers and
a single weak producer.
Molecular typing of E. faecium isolates and the distribu-
tion meroclone- and lineage-specific markers MLVA re-
vealed 12 MLVA types (MTs; Table 4) among 112 invasive
E. faecium isolates, with the most prevalent being MT159,
characteristic for 52 isolates (43.3 %) from 20 hospitals.
Other frequently encountered MTs included 1, 11, and 12.
The subsequent MLST analysis, performed for a group of 46
representative isolates, revealed the presence of 14 STs
(Table 4). The comparative eBURST analysis included four
STs (78, 192, 341, 412) in lineage 78 and nine STs (17, 18, 64,
80, 117, 202, 262, 877, 878) in lineage 17/18; the remaining
ST879 represented a singleton. Isolates of lineage 17/18 were
most often associated with MT1 and MT12, and isolates of
lineage 78 typically had MT159, however, one ST117 isolate
(lineage 17/18) had MT159 (verified by repeated typing). The
acquisition of vancomycin-resistance determinants vanA and
vanB occurred chiefly among isolates of lineage 17/18 (five
out of seven cases). Most of the isolates able to produce
Table 2 Ward type, type of infection and outcome reported for patients with invasive enterococcal infections
E. faecalis (140) E. faecium (112) Other species (7) All
Number of isolates 140 (54.1 %) 112 (43.2 %) 7 259
Type of ward
Surgery 32 (22.9 %) 31 (27.7 %) 3 66 (25.5 %)
Haematology/oncology 20 (14.3 %) 32 (28.6 %) 2 54 (20.8 %)
ICU 29 (20.7 %) 27 (24.1 %) 1 57 (22.0 %)
Internal medicine 29 (20.7 %) 11 (9.8 %) 0 40 (15.4 %)
Other neurology (n = 9), dialysis centres (n= 8), neonatal (n= 5),
gynaecology (n= 4), urology (n= 5), infectious disease (n= 3),
geriatric (n= 2), palliative medicine (n= 1)
30 (21.4 %) 11 (9.8 %) 1 42 (16.2 %)
Type of infection
Bacteraemia, septicaemia, including: 109 (77.8 %) 82 (73.2 %) 4 195 (75.3 %)
Bacteraemia 76 (54.3 %) 63 (56.2 %) 3 142 (54.8 %)
Septicaemia 33 (23.5 %) 19 (16.9 %) 1 53 (20.5 %)
- source abdominal infection 16 (11.4 %) 11 (9.8 %) 2 29 (11.2 %)
- source urinary tract infection 10 (7.1 %) 1 (0.9 %) 0 11 (4.2 %)
- other known source 26 (18.6 %) 18 (16.1 %) 0 44 (17.0 %)
- unknown source 57 (40.7 %) 52 (46.4 %) 0 109 (42.1 %)
Endocarditis 7 (5.1 %) 2 (1.8 %) 0 9 (3.5 %)
Abdominal infections 18 (12.9 %) 22 (19.6 %) 3 43 (16.6 %)
Pleural infections 2 (1.4 %) 2 (1.8 %) 0 4 (1.5 %)
Meningitis 2 (1.4 %) 3 (2.7 %) 0 5 (1.9 %)
Pelvic infections 2 (1.4 %) 1 (0.9 %) 0 3 (1.2 %)
Outcomea
All reported 130 107 6 243
Fatal cases 20 (15.4 %) 23 (21.5 %) 1b 44 (18.1 %)
Cured 33 (25.4 %) 25 (23.4 %) 2 60 (24.7 %)
Under treatment 77 (59.2 %) 59 (55.1 %) 3 139 (57.2 %)
a% of all cases with the known outcome; bE. gallinarum
In the column for each species the % values were calculated separately taking the number of the isolates belonging the each species as 100 %
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biofilm (three out of four) also belonged to this lineage. IS16
and espEfm were detected in all E. faecium isolates, and
intAICEEfm1 for 107 isolates (95.5 %). Thus, the espEfm gene
(verified by sequencing) was present in five isolates negative
for intAICEEfm1. Distribution of genes located within six GDRs
characteristic for ST203 from lineage 78 [12] was assessed
among isolates of E. faecium collected in this study and for
comparative purposes among 52 sewage isolates, not associ-
ated with the hospital meroclone [23]. Significant differences
in the prevalence were found for GDR1, which was more
frequently detected in sewage isolates, and GDR2 and
GDR3, which occurred chiefly among hospital-associated iso-
lates (Table 5). Comparison between two hospital lineages of
E. faecium revealed a significant over-representation of all six
GDRs in lineage 78 in comparison to lineage 17/18.
Sequencing of PCR products for a few randomly-selected
representatives of both lineages and non-hospital E. faecium
for all six GDRs revealed their 100 % identity with the coun-
terparts in ST203 [12].
Discussion
The growing importance of enterococcal infections in hospi-
tals prompted us to perform an enhanced surveillance of en-
terococci causing invasive diseases in selected Polish hospi-
tals in the pre-defined period of time. The clinical presenta-
tions of infections were typical for enterococci, including
mainly bacteraemia and abdominal infections. Similarly to
other reports, our results point out the abdominal infections
as the most frequently observed sources of bacteraemia/
septicaemia; however, the small proportion of E. faecalis
bacteraemia originating from urinary tract (7.1 %) was sur-
prising [24, 25]. This could be due to the relatively high ratio
of bacteraemia with unknown source observed in our study for
both E. faecalis and E. faecium (40.7 % and 46.4 % respec-
tively) in comparison to other reports (E. faecalis 30 % and
21.6 %; E. faecium 39.9 % and 20.7 %) [24, 25]. Collected
clinical data confirmed established risk factors for acquisition
of invasive enterococcal infection, such as advanced age, pre-
vious hospitalization, and ICU stay [13, 24]. In our study, the
majority of patients were male and aged above 50 years, and
most of the fatal cases were observed in this age group. Other
studies have reported similar proportions of patients’ gender
and age distribution [24]. The 14-day mortality rate of 18.1 %
reported in our study corresponded to the 30-day mortality
rates of 18.9 % to 25 % among patients with enterococcal
bacteraemia in other countries [25]; however, it is important
to note that at the 2-week reporting interval the majority of
patients in our study were still under treatment. We observed a
higher mortality in infections caused by E. faecium than
E. faecalis (20.1 % vs 15.4 %), which is in agreement with a
report from Denmark (34.6 % and 21.4 % respectively) [24]
and Spain (30 % and 26 % respectively, among cancer
patients) [26].
While at the rise of enterococcal infections in hospitals in
the 1970s E. faecalis represented the most predominant spe-
cies, contributing to approximately 90 % of infections, more
recently the relative proportion of these two species has been
changing in the favour of E. faecium and is now almost
reaching or even exceeding the parity [26, 27], due to the
increasing incidence of infections caused by E. faecium [24].
This worldwide trend of increasing importance of E. faecium
in HAIs was also observed in the present study, where 54 %
and 43 % of infections were caused by E. faecalis and E.
faecium respectively. For comparison, the ratio of E. faecium
accounted for around 30 % of isolates from blood in our coun-
try during 2001–2004, and increased to around 40 % in 2009–
2013 (http://www.ecdc.europa.eu/en/activities/surveillance/
EARS-Net). This shift in the proportion of E. faecium to
E. faecalis results in the increased overall morbidity of
enterococcal infections, due to a higher fatality ratio of
bacteraemia caused by this species [26], which may be at
least partially associated with frequent resistance of
E. faecium to important anti-enterococcal drugs, such as ampi-



























Fig. 1 The age distribution of
patients and percentage of fatal
cases in each age group
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Table 3 Antimicrobial susceptibility profiles of enterococcal isolates from invasive infections
Species MIC (mg/L) Number of isolates (%) and 95 % confidence intervals of % Ra
Antimicrobial agentb Range MIC50 MIC90 S I
c R 95 % CI
E. faecalis (n = 140)
Ampicillin 0.5–4.0 2.0 4.0 140 (100 %) 0 0 0-3.3
Penicillin 0.125–16.0 2.0 4.0 139 (99.3 %) - 1 (0.7 %) 0-4.5
Vancomycin 0.125–4.0 2.0 4.0 140 (100 %) - 0 0-3.3
Teicoplanin 0.125–0.5 0.125 0.25 140 (100 %) - 0 0-3.3
HLGR 4.0– >1024 1024 >1024 62 (44.29 %) - 78 (55.71 %) 47.1-64.0
HLSR 16.0– >2048 2048 >2048 64 (45.71 %) - 76 (54.29 %) 45.7-62.7
Tetracycline 0.125– >256 128 256 14 (10 %) 2 (1.43 %) 124 (88.57 %) 81.9-93.1
Tigecycline 0.015–0.25 0.062 0.25 140 (100 %) 0 0 0-3.3
Chloramphenicol 0.5–128 8.0 128 97 (69.29 %) 1 (0.71 %) 42 (30 %) 22.7-38.4
Daptomycin 0.125–4.0 1.0 2.0 140 (100 %) - 0 0-3.3
Rifampin 0.25–16.0 2.0 8.0 45 (32.14 %) 37 (26.43 %) 58 (41.43 %) 32.6-49.3
Ciprofloxacin 0.125– >32.0 8.0 >32 56 (40 %) 13 (9.29 %) 71 (50.71 %) 41.5-58.5
Linezolid 0.25–4.0 2.0 4.0 140 (100 %) - 0 0-3.3
Imipenem 0.5-64 16 64 11 (7.9 %) 30 (21.4 %) 99 (70.7 %) 62.3-77.9
Trimethoprim-sulphamethoxazole 0.015-32 4 32 11 (7.9 %) 47 (33.8 %) 81 (58.3 %) 49.6-66.5
E. faecium (n = 112)
Ampicillin 1–>256 64 128 1 (0.89 %) 11 (9.82 %) 110 (89.29 %) 81.7-94.1
Penicillin 0.25– >256 128 256 9 (8.04 %) - 103 (91.96 %) 84.9-96.1
Vancomycin 0.5– >256 2.0 4.0 104 (92.86 %) - 8 (7.14 %) 3.3-14.0
Teicoplanin 0.125–128 0.25 1.0 107 (95.54 %) - 5 (4.46 %) 1.7-10.7
HLGR 4.0– >1024 >1024 >1024 15 (13.39 %) - 97 (86.61 %) 78.6-92.1
HLSR 4.0– >2048 2048 >2048 16 (14.29 %) - 96 (85.71 %) 77.5-91.4
Tetracycline 0.25–256 16 128 49 (43.75 %) 4 (3.57 %) 59 (52.68 %) 43.1-62.1
Tigecycline 0.015–0.5 0.062 0.25 111 (99.11 %) 1 (0.89 %) 0 0-4.1
Chloramphenicol 0.062–32.0 8.0 16 89 (79.46 %) 16 (14.29 %) 7 (6.25 %) 2.7-12.8
Daptomycin 0.062–4.0 2.0 4.0 112 (100 %) 0 0 0.0-4.1
Rifampin 0.062– >128 32 >128 5 (4.46 %) 3 (2.68 %) 104 (92.86 %) 86-96.7
Ciprofloxacin 2.0– >256 256 >256 0 1 (0.89 %) 111 (99.11 %) 94.4-100
Linezolid 1.0–4.0 2.0 4.0 112 (100 %) 0 0 0.0-4.1
Quinupristin-dalfopristin 0.125–16 2.0 4.0 54 (48.2 %) 52 (46.4 %) 6 (%54 %) 2.2-11.8
Other Enterococcus spp. (n= 7)
Ampicillin 0.0625–128.0 16 128 3 0 4 -
Penicillin 0.5–64.0 8 64 6 - 1 -
Vancomycin 0.5–8.0 2 8 4 - 3 -
Teicoplanin 0.125–1.0 0.25 1 7 - 0 -
HLGR 4.0–1024 64 1024 5 - 2 -
HLSR 32.0–2048 256 2048 4 - 3 -
Tetracycline 0.125–64 64 64 2 0 5 -
Tigecycline 0.031–0.062 0.031 0.062 7 0 0 -
Chloramphenicol 0.25–8.0 4 8 7 0 0 -
Daptomycin 0.25–2.0 1 2 7 0 0 -
Rifampin 0.062–64.0 0.5 64 5 0 2 -
Ciprofloxacin 0.125–64.0 4 64 3 0 4 -
Linezolid 0.015–4.0 2 4 7 0 0 -
a S, susceptible; I, intermediate; R, resistant; b HLGR, high-level gentamicin resistance, HLSR, high-level streptomycin resistance; c -, intermediate
category not defined for this compound
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Ampicillin resistance is now very common among hospital E.
faecium, and it proceeded the appearance and constant rise of
vancomycin resistance in the hospitalmeroclone of this species
[11, 28]. In our study, acquired resistance to vancomycin in E.
faecium was still relatively rare (7 %). VREfm have been ob-
served in Poland since the end of the 1990s with an increasing
incidence [19, 29]. The frequency of VRE differs in various
regions of the world, with a high prevalence reported in the US
(up to 80 % of E. faecium) [27] and some European countries,
such as Greece, the UK, and Portugal [28], while a low ratio
(below 1 %) is characteristic for Sweden, The Netherlands,
France, and Spain (http://www.ecdc.europa.eu/en/activities/
surveillance/EARS-Net). We observed a very high
prevalence of high-level resistance to aminoglycosides in
E. faecium, which eliminates the possibility of combined
therapy including aminoglycoside with cell-wall-active agents
(penicillins, glycopeptides) for synergistic bactericidal effect.
Although E. faecalis remains generally susceptible to penicil-
lins, high-level resistance to aminoglycosides exceeded 50 %
in our study, with the same problem for the combined therapy.
Such a phenotype has also been reported for several other
European countries (http://www.ecdc.europa.eu/en/activities/
surveillance/EARS-Net), and our previous analysis of
nosocomial isolates of E. faecalis from six European
countries showed a significant role of two hospital clones in
the spread of high-level aminoglycoside resistance in this spe-
cies [8]. All isolates in the current study showed susceptibility
to linezolid, the drug of last resort in VRE infections, although
resistance to this compound is being observed in our country
for both E. faecalis and E. faecium [30].











Number of isolates analysed by
MLST
STsa Lineage
1 5-7-3-3-2-3 16 10 3 3 8 17; 18; 64; 80;
202
17/18
7 5-7-3-3-2-2 1 1 0 0 1 17 17/18
10 5-7-3-3-3-3 1 1 0 0 1 262 17/18
11 6-7-3-3-2-3 13 8 0 1 3 202 17/18
12 5-7-3-3-1-3 15 8 2 4 6 877; 117 17/18
112 3-7-4-2-1-3 1 1 0 0 1 878 17/18
159 5-7-3-3-1-2 1 1 0 0 1 117 17/18
520 2-7-3-3-1-2 4 4 1 1 2 117 17/18
summary 52 21 6 9 23 17/18
159 5-7-3-3-1-2 51 20 2 11 12 78; 192; 341;
412
78
291 5-7-4-3-1-2 4 2 0 1 1 78 78
334 5-7-3-4-1-2 3 1 0 2 1 78 78
518 5-2-3-3-1-2 1 1 0 0 1 78 78
summary 59 21 2 14 15 78
519 3-7-3-3-2-2 1 1 0 0 1 879 singleton
a novel MTs and STs underlined; b in the order: VNTR1, VNTR2, VNTR7, VNTR8, VNTR9, VNTR10
Table 5 Distribution of GDRs among lineages 17/18 and 78 and among hospital and sewage isolates of E. faecium
lineagea/origin GDR1 (%) GDR2 (%) GDR3 (%) GDR5 (%) GDR6 (%) GDR7 (%) Number of isolates with n GDR loci
n= 0 n = 1 n = 2 n = 3 n = 4 n = 5 n = 6
17/18 (n = 27) 14 (51.2) 16 (59.2) 5 (18.5) 4 (14.8) 6 (22.2) 2 (7.4) 4 12 4 3 3 0 1b
78 (n= 18) 16 (88.9) 18 (100) 15 (83.3) 18 (100) 11 (61.1) 13 (72.2) 0 0 0 2 3 5 8
Pc 0.02 0.005 0.0001 0.00000 0.02 0.00003
ST879 (n= 1) 1 0 1 1 0 1 1
Hospital (n= 46) 31 (67.4) 34 (73.9) 21 (45.6) 23 (50.0) 17 (36.9) 16 (34.8) 4 12 4 5 7 5 9
Sewage (n= 52) 49 (94.2) 0 (0) 5 (9.6) 21 (40.4) 11 (21.1) 11 (21.1) 2 20 13 16 1 0 0
Pd 0.001 0 0.0001 0.4 0.1 0.2
a Based on theMLST data; b verified by repeated typing and GDR sequencing; c differences in GDR distributions between lineages 17/18 and 78 isolates;
d differences in GDR distributions between hospital and sewage isolates
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Selection of particular enterococcal clones, adapted to hos-
pital settings, appears to play a crucial role in the increasing
importance of these pathogens in HAIs, especially in the case
of E. faecium. The rise in the prevalence of this species which
was found in our study prompted us to analyse collected
E. faecium isolates in more detail. The results of MLVA,
MLST and detection of markers, specific for nosocomial
E. faecium such as IS16 [18], espEfm and intAICEEfm1 associ-
ated with a transferable pathogenicity island ICEfm1 [31, 32],
indicated that almost all isolates represented hospital epidemic
meroclone. Circulation of strains belonging to this clone most
likely predates the appearance of the first VRE in Polish hos-
pitals in the late 1990s [19, 29]. EspEfm, a species-specific
variant of the enterococcal surface protein, is involved in bio-
film formation [33] and increases enterococcal virulence in
endocarditis [34]. Although the espEfm gene was present ubiq-
uitously in the studied group, only a minority of isolates were
able to form biofilm under experimental conditions. A recent
study [35] questioned the utility of a polystyrene dish assay
for biofilm formation by E. faecalis, and showed much more
reliable performance of porcine heart valve explants. A similar
system may also be required for E. faecium biofilm studies.
Hospital E. faecium in our study belonged to both major
BAPS groups, corresponding to lineages 17/18 and 78 [10].
The latter, more recently evolving lineage is currently being
isolated in hospitals all over the world [26, 36, 37], and in
Poland it was first observed in 2005 among VREfm [19].
ST78 and its variants are typically associated with MT159
[38, 39], themost prevalentMT in our study. Spread of lineage
78 strains is considered to be a significant factor of the increas-
ing VanB-type vancomycin resistance in Australia [37], and
current detailed genomic analysis of strains representing both
lineages has revealed the presence of seven GDRs, addition-
ally present in a representative of lineage 78 [12]. In this study,
we analysed the distribution of genes characteristic for six
GDRs, with the exception of one region (GDR4) which con-
tains a presumable integrase gene. Genes of two GDRs, name-
ly the gene encoding a riboflavin biosynthesis protein RibD
from GDR2 and the gene encoding a putative phosphosugar
isomerase from GDR3, were significantly more prevalent
among isolates from hospital settings in comparison to sewage
isolates, while the latter were more often carrying the gene of
cadmium-translocating P-type ATPase fromGDR1; it is likely
that the product of this gene provides a selective advantage in
various environments. Among hospital strains, all six
analysed GDRs were over-represented among successful lin-
eage 78; however, genes of GDR5, 6, and 7 were relatively
frequent also among the sewage isolates, suggesting that
E. faecium circulating in the community might have been a
source of such genes for nosocomial strains. Further analyses
are, however, required to verify such a possibility.
In summary, our study provides the data on species distri-
bution, prevalence of resistance, and clonality of enterococcal
invasive isolates, and characterizes patients affected by such
infections. The study on Polish isolates shows the similarity of
invasive, hospital-adapted E. faecium to strains circulating in
other countries, and underlines the importance of permanent
surveillance of the dynamic epidemiological situation
concerning these dangerous opportunistic pathogens. These
data will be the reference for future studies performed in
Poland.
Acknowledgments We thank the representatives of all the centres par-
ticipating in the study: Krzysztof Golec, Anna Onyszk, Katarzyna
Muszyńska, Elżbieta Maćkowiak, Jolanta Zielińska, Małgorzata
Pilarska, Małgorzata Szarata, Krzysztof Burdynowski, Halina
Kondracka-Grabarczyk, Grzegorz Ziółkowski, Aleksandra Renik, Beata
Klonowska, Dorota Kociszewska, Anna Jędrzejewska, Joanna
Humanowska, Małgorzata Kozak, Maria Szymankiewicz, Jolanta
Prawda-Zołotar, Elżbieta Iskra, Anna Mól, Bonita Durnaś, Mirosława
Piotrowska, Zofia Żak-Puławska, Wojciech Żulikowski, Anna
Budzyńska, Julianna Kurlenda, Anita Mądroszyk, Edyta Podsiadły, and
Jolanta Szumilewicz for providing the isolates, and Janetta Top for
assigning new alleles and STs, and for her aid in assigning MTs. This
publication made use of the Enterococcus faeciumMLSTwebsites http://
efaecium.mlst.net/ hosted at Imperial College and developed and funded
by the Wellcome Trust, and http://pubmlst.org/efaecium/ sited at the
University of Oxford and funded by the Wellcome Trust. Parts of this
publication have previously been presented at the 22nd European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
31 March–3 April 2012, London, UK (oral presentation).
Compliance with ethical standards
Funding This study was partially financed by health programme
BNarodowy Program Ochrony Antybiotyków na lata 2011-2015^ from
The Polish Ministry of Health and by the grant SPUB MIKROBANK
from the Polish Ministry of Science and Higher Education.
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval The authors declare that ethical approval was not
required.
Informed consent The authors declare that informed consent was not
required.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond MB (2004) Nosocomial bloodstream infections in US
hospitals: analysis of 24,179 cases from a prospective nationwide
surveillance study. Clin Infect Dis 39(3):309–317. doi:10.1086/
421946
854 Eur J Clin Microbiol Infect Dis (2016) 35:847–856
2. European Centre for Disease Prevention and Control (2013) Point
prevalence survey of healthcare-associated infections and antimi-
crobial use in European acute care hospitals. ECDC, Stockholm.
doi:10.2900/86011
3. Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A
(2010) Mobile genetic elements and their contribution to the emer-
gence of antimicrobial resistant Enterococcus faecalis and
Enterococcus faecium. Clin Microbiol Infect 16(6):541–554. doi:
10.1111/j.1469-0691.2010.03226.x
4. Gordon S, Swenson JM, Hill BC, Pigott NE, FacklamRR, Cooksey
RC, Thornsberry C, Jarvis WR, Tenover FC (1992) Antimicrobial
susceptibility patterns of common and unusual species of entero-
cocci causing infections in the United States. Enterococcal Study
Group. J Clin Microbiol 30(9):2373–2378
5. HomanWL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, Van
Embden JD, Willems RJ (2002) Multilocus sequence typing
scheme for Enterococcus faecium. J Clin Microbiol 40(6):1963–
1971. doi:10.1128/JCM.40.6.1963-1971.2002
6. Ruiz-Garbajosa P, Bonten MJ, Robinson DA, Top J, Nallapareddy
SR, Torres C, Coque TM, Cantón R, Baquero F, Murray BE, del
Campo R, Willems RJ (2006) Multilocus sequence typing scheme
for Enterococcus faecalis reveals hospital-adapted genetic com-
plexes in a background of high rates of recombination. J Clin
Microbiol 44(6):2220–2228. doi:10.1128/JCM.02596-05
7. Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read
TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H,
Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S,
DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W,
Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H,
Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM
(2003) Role of mobile DNA in the evolution of vancomycin-
resistant Enterococcus faecalis. Science 299(5615):2071–2074.
doi:10.1126/science.1080613
8. Kuch A, Willems RJ, Werner G, Coque TM, Hammerum AM,
Sundsfjord A, Klare I, Ruiz-Garbajosa P, Simonsen GS, van Luit-
Asbroek M, Hryniewicz W, Sadowy E (2012) Insight into antimi-
crobial susceptibility and population structure of contemporary hu-
man Enterococcus faecalis isolates from Europe. J Antimicrob
Chemother 67(3):551–558. doi:10.1093/jac/dkr544
9. Willems RJ, Top J, van Santen M, Robinson DA, Coque TM,
Baquero F, Grundmann H, Bonten MJ (2005) Global spread of
vancomycin-resistant Enterococcus faecium from distinct nosoco-
mial genetic complex. Emerg Infect Dis 11(6):821–828. doi:10.
3201/eid1106.041204
10. Willems RJ, Top J, van Schaik W, Leavis H, Bonten M, Sirén J,
Hanage WP, Corander J (2012) Restricted gene flow among hospi-
tal subpopulations of Enterococcus faecium. Ambio 3(4):e00151–
12. doi:10.1128/mBio.00151-12
11. Top J, Willems R, Bonten M (2008) Emergence of CC17
Enterococcus faecium: from commensal to hospital-adapted path-
ogen. FEMS Immunol Med Microbiol 52(3):297–308. doi:10.
1111/j.1574-695X.2008.00383.x
12. Lam MM, Seemann T, Tobias NJ, Chen H, Haring V, Moore RJ,
Ballard S, Grayson LM, Johnson PD, Howden BP, Stinear TP
(2013) Comparative analysis of the complete genome of an epidem-
ic hospital sequence type 203 clone of vancomycin-resistant
Enterococcus faecium. BMC Genomics 14:595. doi:10.1186/
1471-2164-14-595
13. Billington EO, Phang SH, Gregson DB, Pitout JD, Ross T, Church
DL, Laupland KB, Parkins MD (2014) Incidence, risk factors, and
outcomes for Enterococcus spp. blood stream infections: a
population-based study. Int J Infect Dis 26:76–82. doi:10.1016/j.
ijid.2014.02.012
14. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME,
Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist
B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A,
Weber JT, Monnet DL (2012) Multidrug-resistant, extensively
drug-resistant and pandrug-resistant bacteria: an international ex-
pert proposal for interim standard definitions for acquired resis-
tance. Clin Microbiol Infect 18(3):268–281. doi:10.1111/j.1469-
0691.2011.03570.x
15. Tsikrikonis G, Maniatis AN, Labrou M, Ntokou E, Michail G,
Daponte A, Stathopoulos C, Tsakris A, Pournaras S (2012)
Differences in biofilm formation and virulence factors between
clinical and fecal enterococcal isolates of human and animal origin.
Microb Pathog 52(6):336–343. doi:10.1016/j.micpath.2012.03.003
16. Baldassarri L, Cecchini R, Bertuccini L, Ammendolia MG, Iosi F,
Arciola CR, Montanaro L, Di Rosa R, Gherardi G, Dicuonzo G,
Orefici G, Creti R (2001) Enterococcus spp. produces slime and
survives in rat peritoneal macrophages. Med Microbiol Immunol
190(3):113–120
17. Shankar V, Baghdayan AS, Huycke MM, Lindahl G, Gilmore MS
(1999) Infection-derived Enterococcus faecalis strains are enriched
in esp, a gene encoding a novel surface protein. Infect Immun 67(1):
193–200
18. Werner G, Fleige C, Geringer U, van Schaik W, Klare I, Witte W
(2011) IS element IS16 as a molecular screening tool to identify
hospital-associated strains of Enterococcus faecium. BMC Infect
Dis 11:80. doi:10.1186/1471-2334-11-80
19. Sadowy E, Sieńko A,Gawryszewska I, Bojarska A,MalinowskaK,
Hryniewicz W (2013) High abundance and diversity of antimicro-
bial resistance determinants among early vancomycin-resistant
Enterococcus faecium in Poland. Eur J Clin Microbiol Infect Dis
32(9):1193–1203. doi:10.1007/s10096-013-1868-y
20. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC (1993)
Characterization of glycopeptide-resistant enterococci from U.S.
hospitals. Antimicrob Agents Chemother 37(11):2311–2317. doi:
10.1128/AAC.37.11.2311
21. Dahl KH, Simonsen GS, Olsvik O, Sundsfjord A (1999)
Heterogeneity in the vanB gene cluster of genomically diverse
clinical strains of vancomycin-resistant enterococci. Antimicrob
Agents Chemother 43(5):1105–1110
22. Top J, Schouls LM, Bonten MJ, Willems RJ (2004) Multiple-locus
variable-number tandem repeat analysis, a novel typing scheme to
study the genetic relatedness and epidemiology of Enterococcus
faecium isolates. J Clin Microbiol 42(10):4503–4511. doi:10.
1128/JCM.42.10.4503-4511.2004
23. Sadowy E, Luczkiewicz A (2014) Drug-resistant and hospital-
associated Enterococcus faecium from wastewater, riverine estuary
and anthropogenically impacted marine catchment basin. BMC
Microbiol 14:66. doi:10.1186/1471-2180-14-66
24. Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC,
Gradel KO, Søgaard M, Knudsen JD, Danish Collaborative
Bacteraemia Network (DACOBAN) (2014) Incidence, clinical
characteristics and 30-day mortality of enterococcal bacteraemia
in Denmark 2006–2009: a population-based cohort study. Clin
Microbiol Infect 20(2):145–151. doi:10.1111/1469-0691.12236
25. McBride SJ, Upton A, Roberts SA (2010) Clinical characteristics
and outcomes of patients with vancomycin-susceptible
Enterococcus faecalis and Enterococcus faecium bacteraemia-a
five-year retrospective review. Eur J Clin Microbiol Infect Dis
29(1):107–114. doi:10.1007/s10096-009-0830-5
26. Gudiol C, Ayats J, Camoez M, Domínguez MÁ, García-Vidal C,
Bodro M, Ardanuy C, Obed M, Arnan M, Antonio M, Carratalà J
(2013) Increase in bloodstream infection due to vancomycin-
susceptible Enterococcus faecium in cancer patients: risk factors,
molecular epidemiology and outcomes. PLoS One 8(9):e74734.
doi:10.1371/journal.pone.0074734
27. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock
DA, Fridkin SK, National Healthcare Safety Network Team;
Participating National Healthcare Safety Network Facilities
(2008) NHSN annual update: antimicrobial-resistant pathogens
Eur J Clin Microbiol Infect Dis (2016) 35:847–856 855
associated with healthcare-associated infections: annual summary
of data reported to the National Healthcare Safety Network at the
Centers for Disease Control and Prevention, 2006–2007. Infect
Control Hosp Epidemiol 29(11):996–1011, Erratum in: Infect
Control Hosp Epidemiol 30(1):107. doi:10.1086/595835
28. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W,
Johnson A, Klare I, Kristinsson KG, Leclercq R, Lester CH, Lillie
M, Novais C, Olsson-Liljequist B, Peixe LV, Sadowy E, Simonsen
GS, Top J, Vuopio-Varkila J, Willems RJ, Witte W, Woodford N
(2008) Emergence and spread of vancomycin resistance among
enterococci in Europe. Euro Surveill 13(47). http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=19046
29. Hryniewicz W, Szczypa K, Bronk M, Samet A, Hellman A,
Trzcinski K (1999) First report of vanconmycin-resistant
Enterococcus faecium isolated in Poland. Clin Microbiol Infect
5(8):503–505. doi:10.1111/j.1469-0691.1999.tb00181.x
30. Gawryszewska I, Żabicka D, Hryniewicz W, Sadowy E (2014)
Linezolid resistant enterococci – resistance mechanisms and clonal
relatedness. 24th ECCMID 2014. http://www.escmid.org/escmid_
library/online_lecture_library
31. Willems RJ, Homan W, Top J, van Santen-Verheuvel M, Tribe D,
Manzioros X, Gaillard C, Vandenbroucke-Grauls CM, Mascini
EM, van Kregten E, van Embden JD, Bonten MJ (2001) Variant
esp gene as a marker of a distinct genetic lineage of vancomycin-
resistant Enterococcus faecium spreading in hospitals. Lancet
357(9259):853–855. doi:10.1016/S0140-6736(00)04205-7
32. Top J, Sinnige JC,Majoor EA, Bonten MJ,Willems RJ, van Schaik
W (2011) The recombinase IntA is required for excision of esp-
containing ICEEfm1 in Enterococcus faecium. J Bacteriol 193(4):
1003–1006. doi:10.1128/JB.00952-10
33. Heikens E, Bonten MJ, Willems RJ (2007) Enterococcal surface
protein Esp is important for biofilm formation of Enterococcus
faecium E1162. J Bacteriol 189(22):8233–8240. doi:10.1128/JB.
01205-07
34. Heikens E, Singh KV, Jacques-Palaz KD, van Luit-Asbroek M,
Oostdijk EA, Bonten MJ, Murray BE, Willems RJ (2011)
Contribution of the enterococcal surface protein Esp to pathogene-
sis of Enterococcus faecium endocarditis. Microbes Infect 13(14–
15):1185–1890. doi:10.1016/j.micinf.2011.08.006
35. Leuck AM, Johnson JR, Dunny GM (2014) Awidely used in vitro
biofilm assay has questionable clinical significance for enterococcal
endocarditis. PLoS One 9(9):e107282. doi:10.1371/journal.pone.
0107282
36. Hsieh YC, Lee WS, Ou TY, Hsueh PR (2010) Clonal spread of
CC17 vancomycin-resistant Enterococcus faecium with multilocus
sequence type 78 (ST78) and a novel ST444 in Taiwan. Eur J Clin
Microbiol Infect Dis 29(1):25–30. doi:10.1007/s10096-009-0810-9
37. Wardal E, Markowska K, Zabicka D, Wróblewska M, Giemza M,
Mik E, Połowniak-Pracka H, Woźniak A, Hryniewicz W, Sadowy
E (2014) Molecular analysis of vanA outbreak of Enterococcus
faecium in twoWarsaw hospitals: the importance of mobile genetic
elements. Biomed Res Int 2014:575367. doi:10.1155/2014/575367
38. Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb
T, Howden BP, Johnson PD, Bennett CM, Stinear TP, Turnidge JD,
Australian Group on Antimicrobial Resistance (2014) Molecular
epidemiology of enterococcal bacteremia in Australia. J Clin
Microbiol 52(3):897–905. doi:10.1128/JCM.03286-13
39. Werner G, Klare I, Witte W (2007) The current MLVA typing
scheme for Enterococcus faecium is less discriminatory than
MLST and PFGE for epidemic-virulent, hospital-adapted clonal
types. BMC Microbiol 7:28. doi:10.1186/1471-2180-7-28
856 Eur J Clin Microbiol Infect Dis (2016) 35:847–856
